

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Patients on symptomatic medication according to GEMA guidelines (therapeutic steps) before and after receiving omalizumab pre-intraseasonally.

Therapeutic GEMA- step	Without medication	1	2	3	4	5	6
Before omalizumab					3 (9.1%)		30 (90.9%)
After omalizumab	11 (33.3%)		3 (9.1%)	1 (3%)	5 (15.1%)	1 (3%)	12 (36.4%)*
McNemar							5.40
p							0.02